Back to News
Market Impact: 0.2
BAYER AG: AskBio's Viralgen,EpilepsyGTx Partner To Advance AAV Gene Therapy For Epilepsy
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
EpilepsyGTx entered a collaboration with Viralgen to support development and manufacturing of AAV gene therapies for drug-resistant epilepsy. The agreement is a positive operational step for EpilepsyGTx's clinical-development capabilities, though no financial terms, program milestones, or commercial impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- CNBC Daily Open: Apple's new iPhone bends. Bond vigilantes, not so much
- Inside India newsletter: India’s green push aims to boost energy security but exposes China dependency
- Teradyne at Goldman Sachs Communacopia + Technology Conference: ai push widens
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- SailPoint (SAIL) Q2 2027 Earnings Call Transcript
- Oddity Tech (ODD) Q2 2026 Earnings Call Transcript